Quantitative analysis for Crescent Biopharma, Inc. (CBIO) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (64.0) (grade B). 28 signals analyzed (23 differentiated alt-data).
CBIO stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $24.44 | $20.44 | $20.94 |
| 2026-05-11 | $19.81 | $17.68 | $18.52 |
| 2026-05-21 | $20.59 | $18.55 | $20.23 |
| 2026-06-03 | $18.00 | $16.91 | $17.98 |
| 2026-06-15 | $18.35 | $17.50 | $18.19 |
| 2026-06-26 | $18.76 | $17.02 | $18.56 |
| 2026-07-09 | $17.37 | $16.55 | $16.76 |
| 2026-07-21 | $17.56 | $15.63 | $16.64 |
| 2026-07-31 | $15.14 | $13.99 | $14.47 |
| 2026-08-12 | $16.98 | $16.10 | $16.43 |
| 2026-08-24 | $17.51 | $16.79 | $16.97 |
| 2026-09-03 | $22.33 | $18.73 | $20.40 |
How Crescent Biopharma, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| RLMD | Relmada Therapeutics, Inc. | $526M | 46.0 |
| GMRS | GMR Solutions Inc. | $533M | 40.0 |
| CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $501M | — |
| PROK | ProKidney Corp. | $545M | — |
View all Health Care stocks by valuation and signals →
Crescent Biopharma, Inc. (CBIO) scores Buy (64.0), and the composite conceals a 95-point disagreement between its dimensions. It is strongest on technicals at 96 and ML forecast at 95, and weakest on competitive moat at 1. A stock can carry technicals that high while competitive moat sits at 1; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| technicals | 96 |
| ML forecast | 95 |
| analyst consensus | 47 |
| competitive moat | 1 |
SEC filings show 1 filers (14d) in Crescent Biopharma, Inc.. See insider activity methodology for how transaction patterns are analyzed, or view full trading history.
StoQuant analyzes 28 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Crescent Biopharma, Inc. (CBIO): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CBIO"><img src="https://stoquant.com/badge/CBIO.svg" alt="Crescent Biopharma, Inc. (CBIO) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.